Trademark: 90605457
Word
ACCURADX
Status Date
Monday, September 16, 2024
Filing Date
Friday, March 26, 2021
Published for Opposition
Tuesday, December 19, 2023
Abandoned Date
Monday, September 16, 2024
9 Downloadable computer software for bioinformatics analyses of NGS data for research use only and medical diagnostic purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs)
5 genetics, genomics and epigenomics-related reagents for medical diagnostic purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs)
1 genetics, genomics and epigenomics-related reagents for research use, including for nucleic acid and protein sample preparation for next-generation sequencing (NGS)
42 Scientific research, scientific analytical research and scientific research consulting services in the field of next-generation sequencing (NGS) and sample preparation therefor, performance for NGS, DNA and RNA mapping technologies including KAS-seq, Keth-seq, CAP-C, and assisting researchers using of NGS technologies; scientific research services regarding DNA and RNA mapping technologies including KAS-seq, Keth-seq, CAP-C; scientific research consulting services in the field of assisting researchers using of NGS technologies; scientific research, scientific analytical research and scientific research consulting services in the field of medical diagnoses via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs); software as a service (SAAS) services featuring analytic software platforms focusing on bioinformatics analyses of NGS data for research use only and future medical diagnostic purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs)
Mar 30, 2021
New Application Entered
Jul 1, 2021
New Application Office Supplied Data Entered
Nov 4, 2021
Assigned To Examiner
Nov 10, 2021
Non-Final Action Written
Nov 10, 2021
Non-Final Action E-Mailed
Nov 10, 2021
Notification Of Non-Final Action E-Mailed
May 6, 2022
Teas Response To Office Action Received
May 6, 2022
Correspondence Received In Law Office
May 7, 2022
Teas/Email Correspondence Entered
Jul 7, 2022
Assigned To Examiner
Aug 24, 2022
Suspension Letter Written
Aug 24, 2022
Letter Of Suspension E-Mailed
Aug 24, 2022
Notification Of Letter Of Suspension E-Mailed
Apr 5, 2023
Suspension Checked - To Attorney For Action
Aug 4, 2023
Final Refusal Written
Aug 4, 2023
Final Refusal E-Mailed
Aug 4, 2023
Notification Of Final Refusal Emailed
Oct 17, 2023
Teas Request For Reconsideration Received
Oct 17, 2023
Correspondence Received In Law Office
Oct 18, 2023
Teas/Email Correspondence Entered
Nov 7, 2023
Examiners Amendment -Written
Nov 7, 2023
Examiners Amendment E-Mailed
Nov 7, 2023
Notification Of Examiners Amendment E-Mailed
Nov 7, 2023
Examiner's Amendment Entered
Nov 15, 2023
Approved For Pub - Principal Register
Nov 29, 2023
Notification Of Notice Of Publication E-Mailed
Dec 19, 2023
Published For Opposition
Dec 19, 2023
Official Gazette Publication Confirmation E-Mailed
Feb 13, 2024
Noa E-Mailed - Sou Required From Applicant
Sep 16, 2024
Abandonment - No Use Statement Filed
Sep 16, 2024
Abandonment Notice E-Mailed - No Use Statement Filed
Trademark Alertz updated from USPTO on 2030-01-24
